文献速递心脑血管急症重症综合管理与镇静镇痛

院外心脏骤停后神经元特异性烯醇化酶与神经预后不一致:十年分析

Discordant neuron-specific enolase and neurologic outcomes in out-of-hospital cardiac arrest: a decade-long analysis.
PubMed 文献 · Resuscitation · 2026-07-13
一句话结论在目标温度管理的昏迷OHCA幸存者中,NSE峰值≥60 μg/L对不良神经预后特异度达98.5%,但正常NSE组仍有26.4%预后不良,需多模态评估。

这项回顾性队列研究纳入2014至2024年间接受目标温度管理的646例昏迷成人OHCA幸存者,按72小时内NSE峰值分为正常(<17 μg/L)、中间(17-60 μg/L)和高(≥60 μg/L)三组。主要终点为6个月不良神经预后(CPC 3-5)。NSE≥60 μg/L对不良预后的特异度达98.5%。正常NSE组中26.4%仍预后不良,独立相关因素包括高龄、不可除颤心律、非心脏病因、较高PaO2和乳酸升高;中间NSE组71.4%预后不良,独立相关因素包括不可除颤心律、较高初始SOFA评分和较低CT灰白质比。结论提示正常NSE组不良预后主要由年龄和全身生理紊乱驱动,中间NSE组则反映血流动力学打击、器官功能障碍和早期脑水肿的综合效应,强调多模态预后评估的重要性。

要点

  • NSE峰值≥60 μg/L对6个月不良神经预后(CPC 3-5)特异度高达98.5%,可作为强烈提示不良预后的指标。
  • 正常NSE组(<17 μg/L)中仍有26.4%(51/193)出现不良神经预后,不能仅凭NSE正常就判定预后良好。
  • 正常NSE组不良预后独立相关因素:高龄、不可除颤心律、非心脏病因、较高PaO2、乳酸升高。
  • 中间NSE组(17-60 μg/L)71.4%预后不良,独立相关因素:不可除颤心律、较高初始SOFA评分、较低CT灰白质比。
  • 对NSE与神经状态不一致的患者,需结合年龄、心律、病因、氧合、乳酸、SOFA评分及脑CT灰白质比进行多模态预后评估。

适用人群与场景

  • 纳入:2014至2024年间接受目标温度管理的昏迷成人院外心脏骤停(OHCA)幸存者。
  • 排除:原文未提及具体排除标准。

诊断标准与关键阈值

  • 根据72小时内NSE峰值分组:正常<17 μg/L,中间17-60 μg/L,高≥60 μg/L。
  • 不良神经预后定义:6个月时脑功能分类(CPC)评分3-5。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • NSE峰值≥60 μg/L对不良神经预后特异度98.5%,提示此类患者预后极差,需与家属沟通并调整治疗目标。
  • 正常NSE组中26.4%仍出现不良预后,尤其合并高龄、不可除颤心律、非心脏病因、较高PaO2或乳酸升高时,不能因NSE正常而放松监护或过早判定预后良好。

研究设计与关键结果

  • 研究类型:回顾性队列研究;样本量:646例;中心数:原文未提及;人群:接受目标温度管理的昏迷成人OHCA幸存者。
  • 分组:正常NSE组193例(29.9%),中间NSE组182例(28.2%),高NSE组271例(41.9%)。
  • 主要终点:6个月不良神经预后(CPC 3-5);NSE≥60 μg/L特异度98.5%。
  • 正常NSE组不良预后26.4%(51/193),独立相关因素:高龄、不可除颤心律、非心脏病因、较高PaO2、乳酸升高。
  • 中间NSE组不良预后71.4%(130/182),独立相关因素:不可除颤心律、较高初始SOFA评分、较低CT灰白质比。

证据类型、等级与局限

  • 证据类型:回顾性队列研究;证据等级或推荐强度:原文未提及。
  • 局限:回顾性设计、单中心(原文未明确中心数,但为十年单机构分析)、样本量646例,结论需前瞻性验证。

对床旁实践的改变

  • NSE峰值≥60 μg/L高度提示6个月不良神经预后(特异度98.5%),可辅助与家属沟通预后及考虑限制无效治疗。
  • NSE正常(<17 μg/L)不能单独用于判定预后良好,尤其当患者高龄、不可除颤心律、非心脏病因、PaO2较高或乳酸升高时,仍需密切监测和综合评估。
  • 对NSE处于中间水平(17-60 μg/L)的患者,应结合初始SOFA评分和脑CT灰白质比等多模态指标进行预后判断,避免单一指标误导。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

AIM: To characterize the clinical profiles of out-of-hospital cardiac arrest (OHCA) survivors stratified according to peak neuron-specific enolase (NSE) concentrations measured within 72 h of arrest, and to identify independent clinical determinants of outcomes in patients exhibiting discordance between NSE levels and neurological status.

METHODS: This retrospective cohort study included comatose adult OHCA survivors who underwent targeted temperature management between 2014 and 2024. Patients were categorized based on peak NSE levels into normal (<17 μg/L), intermediate (17-60 μg/L), and high (≥60 μg/L) groups. The primary endpoint was poor neurological outcome at 6 months, defined as a Cerebral Performance Category score of 3-5. Least Absolute Shrinkage and Selection Operator penalized logistic regression was performed.

RESULTS: Among 646 patients, 193 (29.9%) had normal, 182 (28.2%) intermediate, and 271 (41.9%) high NSE levels. The specificity of a peak NSE ≥60 μg/L for poor neurological outcomes was 98.5%. Within the normal NSE group, 26.4% (51/193) had poor outcomes, independently associated with older age, non-shockable rhythm, non-cardiac etiology, higher PaO2, and elevated lactate. In the intermediate NSE group, 71.4% (130/182) had poor outcomes, independently associated with a non-shockable rhythm, higher initial Sequential Organ Failure Assessment scores, and a lower gray-to-white matter ratio on brain computed tomography.

CONCLUSION: In patients with normal NSE levels, poor outcomes appear to be driven primarily by age and systemic physiological derangements. In the intermediate NSE group, outcomes reflect the combined effects of the initial hemodynamic insult, systemic organ dysfunction, and early cerebral edema, highlighting the importance of a multimodal prognostic approach.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Lee DH, Ryu SJ, Lee BK, et al. Discordant neuron-specific enolase and neurologic outcomes in out-of-hospital cardiac arrest: a decade-long analysis. Resuscitation. 2026. PMID: 42442598. doi:10.1016/j.resuscitation.2026.111205

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。